A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Perifosine (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors AOI Pharmaceuticals
- 18 Jun 2012 Data from this trial has been published in the June 2012 issue of Cancer, according to an AEterna Zentaris media release.
- 17 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2011 Planned End Date changed from 1 Sep 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.